Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.
暂无分享,去创建一个
F. Kabbinavar | H. Hurwitz | L. Fehrenbacher | W. Novotny | N. Meropol | S. Griffing | E. Bergsland | G. Liebérman
[1] N. Ferrara,et al. The biology of vascular endothelial growth factor. , 1997, Endocrine reviews.
[2] M Ancukiewicz,et al. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. , 2000, Cancer research.
[3] Y. Maehara,et al. Microvessel quantification and its possible relation with liver metastasis in colorectal cancer , 1996, Cancer.
[4] J. Godwin,et al. Some prognostic factors in survival of patients with cancer of the colon and rectum. , 1975, Journal of chronic diseases.
[5] J. Folkman,et al. Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. , 1991, The New England journal of medicine.
[6] O. Dent,et al. A multivariate analysis of clinical and pathological variables in prognosis after resection of large bowel cancer , 1985, The British journal of surgery.
[7] Y. Oshika,et al. © 1998 Cancer Research Campaign , 2022 .
[8] F Pozza,et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. , 1992, Journal of the National Cancer Institute.
[9] L. Ellis,et al. Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. , 1997, Archives of surgery.
[10] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.
[11] E. McFadden,et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.
[12] N. Petrelli,et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] S. Ellenberg,et al. A randomized study of oral nutritional support versus ad lib nutritional intake during chemotherapy for advanced colorectal and non-small-cell lung cancer. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] S. Akiba,et al. Angiogenesis as an unfavorable prognostic factor in human colorectal carcinoma , 1996, Cancer.
[15] J. Breed,et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] L. Ellis,et al. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. , 1995, Cancer research.
[17] Scott Kurtzman,et al. Angiogenesis in normal tissue adjacent to colon cancer , 1998, Journal of surgical oncology.
[18] L. Ellis,et al. Molecular determinants in the biology of liver metastasis. , 1996, Surgical oncology clinics of North America.
[19] R. Warren,et al. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. , 1995, The Journal of clinical investigation.
[20] T. A. McPherson,et al. Effect of sex and reproductive history on the survival of patients with colorectal cancer. , 1982, Journal of Chronic Diseases.
[21] S. Kumar,et al. Prognostic relevance of microvessel density in colorectal tumours. , 1999, Oncology reports.
[22] R. Muraoka,et al. Tumor angiogenesis and mode of metastasis in patients with colorectal cancer. , 1997, Cancer research.
[23] G. Sledge,et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] S. Leurgans,et al. Tumor Angiogenesis as a Predictor of Recurrence and Survival in Patients with Node‐Negative Colon Cancer , 1995, Annals of surgery.
[25] S. Hong,et al. Tumor Angiogenesis as a Prognostic Predictor in Colorectal Carcinoma with Special Reference to Mode of Metastasis and Recurrence , 1998, Oncology.
[26] L. Saltz,et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. , 2000, The New England journal of medicine.
[27] K. Hillan,et al. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. , 1999, Anticancer research.
[28] D. Eberhard,et al. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. , 2000, Cancer research.
[29] R. James,et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial , 2000, The Lancet.
[30] M. Levine,et al. Prevention of Thrombotic Disorders in Cancer Patients Undergoing Chemotherapy , 1997, Thrombosis and Haemostasis.